Henry Schein Chair and Stan Bergman retired in February 2026 as CEO after holding the position since 1989, the year this photo was taken. [Photo courtesy of Henry Schein]
The Melville, New York-based medical product supplier is the 11th-largest medical device company in the world, according to Medical Design & Outsourcing’s 2025 Medtech Big 100 ranking by revenue.
Since then, Henry Schein increased its annual sales by 4% to $13.2 billion for fiscal 2025, which ended on Dec. 27, 2025.
It was the company’s last full year under the leadership of CEO Stan Bergman, who announced in July 2025 that he would retire from the top spot but remain board chair. Bergman joined Henry Schein as chief financial officer in 1980 and became CEO in 1989.
Fred Lowery [Photo courtesy of Henry Schein]
Recruiting and retaining top talent — both at the executive and engineering level — is crucial in the medtech industry, but employee compensation is kept secret in most cases. Medical Design & Outsourcing tracks and analyzes these pay figures when disclosed by major device developers and manufacturers.
Henry Schein executive pay
Stan Bergman [Photo courtesy of Henry Schein]
As CEO and chair, Bergman received $12 million in total compensation in 2025, up 3% from the previous year.
Bergman’s pay package included a $1.7 million salary, $7.7 million in stock awards, a $2.3 million cash performance bonus and $252,864 in other compensation.
While he’s not included in the 2025 executive pay disclosure because he hadn’t yet joined the company, Lowery was hired with an annual base salary of $1.25 million and a target annual incentive bonus opportunity of at least $1.875 million, according to an SEC filing detailing his employment agreement.
Mark Mlotek [Photo courtesy of Henry Schein]
Henry Schein EVP and Chief Strategy Officer Mark Mlotek’s 2025 compensation rose 3% to $3.7 million.
Mlotek’s pay package included a $750,000 salary, $2 million in stock awards, a $901,039 cash performance bonus and $36,532 in other compensation.
Henry Schein EVP and COO Michael Ettinger received $3.4 million in total compensation in 2025, down 1% year over year.
Michael Ettinger [Photo courtesy of Henry Schein]
Henry Schein CEO of Global Distribution and Technology Andrea Albertini received $3.4 million in total compensation for 2025.
Albertini’s compensation included a $712,500 salary, a $375,000 bonus, $1.6 million in stock awards, $561,660 cash performance bonus and $118,036 in other compensation.
Andrea Albertini [Photo courtesy of Henry Schein]
South’s pay package included a $640,000 salary, $1.5 million in stock awards, a $509,166 in cash performance bonus and $28,130 in other compensation.
“The company’s executive officer compensation program is designed to, among other things, align rewards with the achievement of the company’s strategic plan,” the company said in the filing that contains its executive compensation disclosure.
Ron South [Photo courtesy of Henry Schein]
Henry Schein’s median worker pay and CEO pay ratio
The SEC requires publicly traded companies to calculate the gap between CEO compensation and pay for its median employee.
To determine its median employee pay, Henry Schein used data as of Oct. 1, 2025. Its calculations excluded 1,050 employees from Chile, China, Iberia (Spain and Portugal), Mexico and Thailand. As of that date, and considering the exclusions, the company had approximately 10,200 U.S. employees and approximately 11,600 non-U.S. employees.
Using these figures, Henry Schein reported a total annual compensation for the median employee of $78,954 in fiscal 2025, up 3% from the previous year.
Against Bergman’s total compensation of more than $12 million in 2025, the ratio of CEO pay to median employee pay totaled 152 to 1. This ratio equals last year’s, which had significantly widened from 132:1 in 2023.
At other medtech companies that offer more details about their median workers than required by the SEC pay disclosure rules, those median medtech workers often hold technical roles such as device design or engineering.
Henry Schein investors will cast advisory “say-on-pay” votes on the company’s executive compensation practices at the May 21, 2026 annual meeting. Shareholders overwhelmingly voted in support of the company’s executive pay the year before.
More medtech compensation analysis for CEOs, top-paid executives and median workers
- Abbott’s device leader pay climbs again with double-digit sales growth
- Medtech CDMO Integer discloses executive pay after new CEO steps in
- Cardinal Health reported a big increase in median worker pay
- GE HeathCare discloses CEO pay decrease but increases for other execs and the median employee
- BD reports lower CEO pay but increases for other execs and the median worker
- Johnson & Johnson discloses executive pay, denies them a talc fight ‘windfall’
- Boston Scientific CEO pay rises again along with median employee pay
- Intuitive discloses CEO pay with new leader at the helm
- Medtronic discloses pay for Diabetes leaders ahead of MiniMed IPO
- Medline discloses executive pay and potential severance payouts ahead of IPO
- Medtronic reports double-digit pay hikes for CEO Geoff Martha and other top executives
- Philips CEO pay dropped in 2024 as Respironics recall fallout continued
